Sacituzumab govitecan (IMMU-132) in uterine serous carcinoma

Chanhee Han; Anna Bianchi; Stefania Bellone; Gary Altwerger; Gulden Menderes; Burak Zeybek; Kaitlin Haines; Salvatore Lopez; Masoud Azodi; Babak Litkouhi

doi:https://doi.org/10.1016/j.ygyno.2019.04.152

doi.org/10.1016/j.ygyno.2019.04.152

Sacituzumab govitecan (IMMU-132) in uterine serous carcinoma

,

,

..., Babak Litkouhi

16

Gynecologic Oncology4.70

Volume: 154, Pages: 64 - 64

Published: Jun 1, 2019

Abstract

Objective: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with poor prognosis. Sacituzumab govitecan (IMMU-132) is a novel antibody-drug conjugate (ADC) targeting trophoblast antigen 2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors including USC, to deliver SN-38, the active metabolite of irinotecan. The objective of this study was to preclinically evaluate the efficacy of IMMU-132...

Paper Fields

Paper Details

Title

Sacituzumab govitecan (IMMU-132) in uterine serous carcinoma

DOI

doi.org/10.1016/j.ygyno.2019.04.152

Published Date

Jun 1, 2019

Journal

Gynecologic Oncology

Volume

154

Pages

64 - 64

Citation AnalysisPro

You’ll need to upgrade your plan to Pro

Looking to understand the true influence of a researcher’s work across journals & affiliations?

Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.

Learn more

Notes

History